334 related articles for article (PubMed ID: 26757188)
1. Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ɛ4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease.
Vijayaraghavan S; Darreh-Shori T; Rongve A; Berge G; Sando SB; White LR; Auestad BH; Witoelar A; Andreassen OA; Ulstein ID; Aarsland D
J Alzheimers Dis; 2016; 50(2):567-76. PubMed ID: 26757188
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease.
Lane R; Feldman HH; Meyer J; He Y; Ferris SH; Nordberg A; Darreh-Shori T; Soininen H; Pirttilä T; Farlow MR; Sfikas N; Ballard C; Greig NH
Pharmacogenet Genomics; 2008 Apr; 18(4):289-98. PubMed ID: 18334913
[TBL] [Abstract][Full Text] [Related]
3. Interaction between Apolipoprotein E and Butyrylcholinesterase Genes on Risk of Alzheimer's Disease in a Prospective Cohort Study.
Chuang YF; Varma V; An Y; Tanaka T; Davatzikos C; Resnick SM; Thambisetty M
J Alzheimers Dis; 2020; 75(2):417-427. PubMed ID: 32250307
[TBL] [Abstract][Full Text] [Related]
4. Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.
De Beaumont L; Pelleieux S; Lamarre-Théroux L; Dea D; Poirier J;
J Alzheimers Dis; 2016 Oct; 54(3):913-922. PubMed ID: 27567841
[TBL] [Abstract][Full Text] [Related]
5. No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases.
Maetzler W; Keller S; Michelis J; Koehler N; Stransky E; Becker C; Schulte C; Melms A; Gasser T; Berg D
Neurobiol Dis; 2009 Aug; 35(2):296-301. PubMed ID: 19481150
[TBL] [Abstract][Full Text] [Related]
6. BuChE-K and APOE epsilon4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline.
Lane R; He Y; Morris C; Leverenz JB; Emre M; Ballard C
Mov Disord; 2009 Feb; 24(3):392-400. PubMed ID: 19006190
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease.
Darreh-Shori T; Siawesh M; Mousavi M; Andreasen N; Nordberg A
J Alzheimers Dis; 2012; 28(2):443-58. PubMed ID: 22012848
[TBL] [Abstract][Full Text] [Related]
8. Plasma butyrylcholinesterase activity: a possible biomarker for differential diagnosis between Alzheimer's disease and dementia with Lewy bodies?
Josviak ND; Batistela MS; Souza RKM; Wegner NR; Bono GF; Sulzbach CD; Simão-Silva DP; Piovezan MR; Souza RLR; Furtado-Alle L
Int J Neurosci; 2017 Dec; 127(12):1082-1086. PubMed ID: 28504037
[TBL] [Abstract][Full Text] [Related]
9. Effect of apolipoprotein E and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease.
Patterson CE; Todd SA; Passmore AP
Pharmacogenomics J; 2011 Dec; 11(6):444-50. PubMed ID: 20644562
[TBL] [Abstract][Full Text] [Related]
10. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment.
Sokolow S; Li X; Chen L; Taylor KD; Rotter JI; Rissman RA; Aisen PS; Apostolova LG
J Alzheimers Dis; 2017; 56(1):229-237. PubMed ID: 27911294
[TBL] [Abstract][Full Text] [Related]
11. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.
Holmes C; Ballard C; Lehmann D; David Smith A; Beaumont H; Day IN; Nadeem Khan M; Lovestone S; McCulley M; Morris CM; Munoz DG; O'Brien K; Russ C; Del Ser T; Warden D
J Neurol Neurosurg Psychiatry; 2005 May; 76(5):640-3. PubMed ID: 15834019
[TBL] [Abstract][Full Text] [Related]
12. No association between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Ki CS; Na DL; Kim JW; Kim HJ; Kim DK; Yoon BK
Am J Med Genet; 1999 Apr; 88(2):113-5. PubMed ID: 10206226
[TBL] [Abstract][Full Text] [Related]
13. The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease.
Ballard C; O'Brien J; Morris CM; Barber R; Swann A; Neill D; McKeith I
Int J Geriatr Psychiatry; 2001 May; 16(5):499-503. PubMed ID: 11376466
[TBL] [Abstract][Full Text] [Related]
14. Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Han HJ; Kwon JC; Kim JE; Kim SG; Park JM; Park KW; Park KC; Park KH; Moon SY; Seo SW; Choi SH; Cho SJ
Eur Neurol; 2015; 73(1-2):23-8. PubMed ID: 25376930
[TBL] [Abstract][Full Text] [Related]
15. Interaction between CYP19 aromatase and butyrylcholinesterase genes increases Alzheimer's disease risk.
Combarros O; Riancho JA; Infante J; Sañudo C; Llorca J; Zarrabeitia MT; Berciano J
Dement Geriatr Cogn Disord; 2005; 20(2-3):153-7. PubMed ID: 16020944
[TBL] [Abstract][Full Text] [Related]
16. Synergy between the alteration in the N-terminal region of butyrylcholinesterase K variant and apolipoprotein E4 in late-onset Alzheimer's disease.
Jasiecki J; Limon-Sztencel A; Żuk M; Chmara M; Cysewski D; Limon J; Wasąg B
Sci Rep; 2019 Mar; 9(1):5223. PubMed ID: 30914707
[TBL] [Abstract][Full Text] [Related]
17. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease.
Lehmann DJ; Johnston C; Smith AD
Hum Mol Genet; 1997 Oct; 6(11):1933-6. PubMed ID: 9302273
[TBL] [Abstract][Full Text] [Related]
18. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease.
Raygani AV; Zahrai M; Soltanzadeh A; Doosti M; Javadi E; Pourmotabbed T
Neurosci Lett; 2004 Nov; 371(2-3):142-6. PubMed ID: 15519745
[TBL] [Abstract][Full Text] [Related]
19. Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.
Yoo HB; Lee HW; Shin S; Park SW; Choi JS; Jung HY; Cha J; Lee JM; Lee JY
Curr Alzheimer Res; 2014 Feb; 11(2):137-44. PubMed ID: 24479631
[TBL] [Abstract][Full Text] [Related]
20. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease.
Yamamoto Y; Yasuda M; Mori E; Maeda K
J Neurol Neurosurg Psychiatry; 1999 Jul; 67(1):94-6. PubMed ID: 10369830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
